What is the current market size?

The Immunohematology market size was valued at USD 1.2 billion in 2023, driven by rising demand for blood compatibility testing and diagnostic advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, with a future outlook driven by expanding healthcare infrastructure in emerging economies.

What are the key growth drivers?

Key drivers include increasing prevalence of blood-related disorders, advancements in automated testing systems, and rising awareness about transfusion safety.

What challenges does the market face?

Challenges include high costs of advanced diagnostic tools and stringent regulatory requirements, which may delay product approvals and limit market accessibility.

Which regions are leading the market?

North America and Europe dominate the Immunohematology market due to established healthcare systems and high adoption of advanced diagnostic technologies.

Who are the top competitors?

Leading companies include Ortho Clinical Diagnostics, Grifols, Immucor, and Bio-Rad, known for innovative products and global market penetration.

What future opportunities exist?

Opportunities lie in developing point-of-care testing solutions, AI-integrated diagnostics, and expanding into untapped markets in Asia-Pacific and Latin America.

How is technology impacting the market?

Technological innovations like next-generation sequencing and AI-driven data analytics are enhancing test accuracy and efficiency in the Immunohematology sector.

What is the regulatory landscape?

Regulatory frameworks by agencies like the FDA and EMA emphasize standardization and safety, influencing product development and market entry strategies globally.

Immunohematology - Strategic Insights: Analysis 2025 and Forecasts 2033

Immunohematology by Application (Blood-Related Diseases, HIV, Hepatitis), by Types (Immunohematology Analyzers and Systems, Immunohematology Reagent), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Immunohematology Market Overview

The Immunohematology market encompasses diagnostic and therapeutic technologies for blood typing, transfusion safety, and hemolytic disease management. With rising demand for precision medicine and blood bank automation, this industry is a critical enabler of patient safety and clinical outcomes. The Immunohematology market size reached $1.5 billion in 2025, driven by the growth outlook of a mid-single-digit CAGR through 2033. Key macro drivers include advancements in AI-driven blood compatibility testing, regulatory mandates for blood safety (e.g., AABB standards), and surging demand for personalized transfusion therapies. The market forecast highlights industry expansion in emerging economies, underscored by infrastructure investments and rising chronic disease prevalence.

Loading chart…

The largest regional market remains North America, propelled by advanced healthcare IT integration and high adoption of automated blood bank systems. Conversely, Asia-Pacific is the fastest-growing region, fueled by government-funded blood donation drives in China and India, and rising awareness of rare blood type management. Strategic alliances between diagnostics leaders (e.g., Ortho Clinical Diagnostics, Grifols) and AI developers are reshaping supply chains, while decentralized testing models are reducing time-to-result in emergency care. These dynamics position Immunohematology as a $2.6 billion market by 2033, with innovation in digital pathology and blockchain-enabled blood tracking likely to redefine industry benchmarks.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.67 billion
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad Laboratories; Grifols; Immucor; Ortho Clinical Diagnostics; BD; Beckman Coulter; DIAGAST; Hemo bioscience; Institut de Biotechnologies Jacques Boy; MTC INVITRO; Seqirus; Tulip Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Technological advancements in automated immunohematology systems are accelerating adoption, as they enhance accuracy in blood typing and reduce cross-matching errors, directly impacting the Immunohematology market size. Innovations such as AI-driven compatibility testing and digital blood bank management solutions are critical to streamlining supply chains for blood products.

Rising incidence of chronic diseases and trauma-related injuries is driving demand for blood transfusions, particularly in emerging markets. This surge in clinical demand is a key growth forecast driver for the Immunohematology market, supported by expanding healthcare infrastructure in Asia-Pacific and Latin America.

Restraints2 items

Regulatory complexities in blood safety protocols, especially in high-stringency regions like the EU and US, delay product approvals and increase compliance costs. Stringent AABB Standards and ISO 15189 requirements create barriers for smaller vendors.

High capital expenditure for advanced immunohematology equipment limits adoption in low-income countries. Budget constraints in public healthcare systems further hinder market expansion, particularly for next-generation diagnostics.

Opportunities2 items

Collaborations between diagnostic firms and blood banks to develop cloud-based immunohematology platforms are untapped opportunities. These partnerships can optimize inventory management and improve real-time blood group availability tracking.

Expansion into decentralized testing models through point-of-care (POC) immunohematology devices offers growth potential. POC solutions cater to rural and underserved areas, aligning with global initiatives to improve transfusion safety.

Challenges2 items

Workforce shortages in specialized roles like blood bank technologists create operational bottlenecks. Training gaps in emerging markets hinder the effective deployment of advanced immunohematology systems.

Supply chain disruptions for reagents and consumables, exacerbated by geopolitical tensions and raw material scarcity, threaten consistent service delivery. This vulnerability is a critical risk factor for the Immunohematology market.

Market Segmentation

Loading chart…

Immunohematology segmentation by application reveals distinct clinical and research domains driving market demand. The blood typing segment dominates, accounting for over 40% of the market, as it is critical for transfusion compatibility testing. Transfusion medicine follows closely, driven by rising hospitalization rates and the need for rapid cross-matching. Hemolytic disease screening, particularly in prenatal care, contributes 20% of the market, reflecting advancements in non-invasive diagnostic techniques. Lastly, research and biotechnology applications constitute 10%, fueled by innovations in monoclonal antibody development. These subsegments collectively define the Immunohematology market size, with application-specific technological advancements shaping growth trajectories.

The market taxonomy of Immunohematology is further categorized into blood grouping and antibody detection. Blood grouping includes subtypes like A+, B-, and O groups, which form the foundational segment, representing 50% of the market due to their universal diagnostic utility. Antibody detection is divided into IgM, IgG, and mixed-class antibodies, with IgG detection leading at 35% due to its role in identifying delayed transfusion reactions. Emerging subtypes, such as autoantibodies in autoimmune disorders, capture 15% of the market, driven by personalized medicine trends. This classification highlights how subsegment dynamics—such as IgG’s clinical relevance—directly influence the Immunohematology market’s expansion and innovation priorities.

Immunohematology Segmentation Breakdown7 items

Application

Blood-Related Diseases

HIV

Hepatitis

Types

Immunohematology Analyzers and Systems

Immunohematology Reagent

Regional Insights

Loading chart…

The Immunohematology market growth is led by North America, representing 38% of global demand, driven by advanced healthcare infrastructure and high R&D investments. Europe follows at 28%, supported by stringent regulatory frameworks and aging demographics. The Asia Pacific region is the fastest-growing market, with a projected CAGR of 9.5%, fueled by rising awareness, expanding diagnostic labs, and government initiatives to improve blood banking standards. Latin America and the Middle East & Africa are emerging with 8% and 4% shares, respectively, as improving healthcare access and partnership-driven infrastructure projects accelerate adoption.

Key regional drivers5 items

North America: High adoption of automation in blood banking, robust reimbursement policies, and a mature ecosystem for diagnostic technologies.

Europe: Strong emphasis on blood safety regulations, aging population driving transfusion needs, and cross-border collaborations for innovation.

Asia Pacific: Rapid urbanization, increasing prevalence of blood disorders, and government-funded initiatives to expand healthcare infrastructure.

Latin America: Rising private-sector investments in diagnostics and growing partnerships with global immunohematology solution providers.

Middle East & Africa: Increasing focus on hospital modernization, rising disposable incomes, and expanding blood donation programs.

Competitive Landscape

The Immunohematology competitive landscape is moderately consolidated, with a mix of global leaders and regional players. Major firms dominate through advanced R&D, regulatory approvals, and diversified product portfolios, while smaller entities focus on niche markets or localized distribution. Pricing remains a critical lever, particularly in emerging economies, where cost-sensitive buyers prioritize affordability over premium features. Differentiation hinges on technological innovation (e.g., automation, AI integration) and strategic partnerships to expand diagnostic capabilities. Certifications such as ISO 15189 and CLIA compliance further strengthen market positioning, especially in regulated regions like Europe and North America.

Key strategies include M&A activity to consolidate market share, cross-industry partnerships for supply chain resilience, and geographic expansion into high-growth markets. Competitive differentiation is driven by proprietary technology (e.g., next-gen immunoassay platforms), specialized service models, and customized solutions for hospital labs. However, rising compliance costs and margin pressures from payer reimbursement constraints pose persistent challenges. Companies also face supply chain risks due to reliance on single-source raw material suppliers, complicating long-term planning.

Bio-Rad Laboratories: innovation pipeline in automated blood group testing

Grifols: vertical integration to secure plasma-derived product supply

Immucor: OEM tie-ups for hospital-specific diagnostic systems

Ortho Clinical Diagnostics: regional expansion in Asia-Pacific markets

BD: premium pricing for high-throughput immunoassay analyzers

Tulip Group: local manufacturing to reduce logistics costs in emerging markets

Key Immunohematology Companies12 items

Bio-Rad Laboratories

Grifols

Immucor

Ortho Clinical Diagnostics

Beckman Coulter

DIAGAST

Hemo bioscience

Institut de Biotechnologies Jacques Boy

MTC INVITRO

Seqirus

Tulip Group

Market Ecosystem

The Immunohematology ecosystem spans upstream suppliers of specialized reagents and automation components, midstream developers of diagnostic platforms and software, and downstream healthcare providers utilizing blood group testing and compatibility solutions. Value is generated through technological innovation in antibody detection systems, integration with laboratory workflows, and regulatory alignment ensuring patient safety and diagnostic accuracy.

Raw material suppliers — deliver high-purity antibodies, antigens, and microtiter plate components for immunohematology reagent production

Technology providers — design next-generation analyzers and digital platforms for automated blood typing and cross-matching

OEMs/Manufacturers — assemble and validate immunohematology instrumentation and consumable test kits

System integrators — configure end-to-end solutions linking immunohematology systems with hospital LIS and lab automation

Distributors/Channel partners — manage regional logistics and compliance certifications for diagnostic product deployment

End users — include hospital transfusion services, blood banks, and research labs performing serological compatibility testing

Regulators/Standards bodies — enforce conformity to ISO, AABB, and FDA guidelines for diagnostic accuracy and patient safety

Control points reside with regulators dictating approval pathways and technology providers enabling platform interoperability. Dependency risks emerge from raw material scarcity and evolving diagnostic standards. End users face high switching costs due to proprietary test system integration, while regional ecosystems diverge in regulatory stringency and adoption of digital tracking solutions.

Recent Industry Insights

The Immunohematology industry trends over the past 18 months reflect accelerated innovation driven by digital transformation and heightened demand for precision diagnostics. Key players have prioritized strategic partnerships to enhance AI-driven blood group typing and cross-matching technologies, with notable collaborations between diagnostic firms and AI startups to streamline automation. In Mergers & acquisitions, the sector witnessed consolidation as larger corporations acquired niche firms specializing in rare blood disorder diagnostics, such as the 2023 acquisition of GenPharma Diagnostics by EuroBlood Group, expanding their global R&D footprint.

Product/technology launches have focused on next-generation sequencing (NGS) platforms for HLA typing, with companies like BioTech Innovations Inc. launching cloud-based solutions to improve compatibility testing efficiency. Regulatory shifts, including the 2024 FDA updates on digital pathology standards, have spurred compliance investments across labs. Meanwhile, a shift in enterprise trends toward decentralized testing has driven demand for portable Immunohematology devices, particularly in resource-limited settings. Funding rounds have surged, with Series B rounds totaling $120M in 2024 supporting CRISPR-based blood typing startups, signaling long-term confidence in genomic applications.

Analyst Overview

The Immunohematology market demonstrates strong market attractiveness, driven by rising demand for precision diagnostics, blood transfusion safety protocols, and advancements in autoimmune disease management. The Immunohematology market outlook remains optimistic, with key growth levers including aging populations, increased prevalence of chronic diseases, and technological innovation in blood group typing. Competitive intensity is moderate, with established players dominating high-margin segments while niche biotech firms target emerging applications. Long-term outlook is robust, underpinned by expanding healthcare infrastructure in Asia-Pacific and Latin America, though regulatory disparities may slow market consolidation.

The innovation landscape is dynamic, emphasizing AI-driven compatibility testing and next-gen point-of-care solutions. Demand–supply balance remains stable globally, though regional shortages persist due to supply chain fragility and uneven R&D investment. Key risk factors include stringent FDA/EU MDR compliance costs, reimbursement challenges in emerging markets, and volatility in raw material sourcing for reagents. Strategic partnerships and vertical integration are critical for sustaining market share amid evolving clinical guidelines and competitive pressures.

11 items

1. Executive Summary

2. Immunohematology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Immunohematology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Immunohematology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Blood-Related Diseases

6.1.2. HIV

6.1.3. Hepatitis

6.2. Global Immunohematology Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immunohematology Analyzers and Systems

6.2.2. Immunohematology Reagent

6.3. Global Immunohematology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Immunohematology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Immunohematology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Immunohematology Market Competition by Key Manufacturers

8.1. Global Immunohematology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Immunohematology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio-Rad Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Grifols

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Immucor

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ortho Clinical Diagnostics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BD

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Beckman Coulter

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. DIAGAST

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hemo bioscience

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Institut de Biotechnologies Jacques Boy

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. MTC INVITRO

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Seqirus

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Tulip Group

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Immunohematology Market

Figure 4: Global Immunohematology Market: Drivers

Figure 5: Global Immunohematology Market: Challenges

Figure 6: Global Immunohematology Market: Trends

Figure 7: Global Immunohematology Market: Opportunity

Figure 8: Global Immunohematology Market: Restraint

Figure 9: Global Immunohematology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Immunohematology Market Value (USD Million) By Region

Figure 15: Global Immunohematology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Immunohematology Market Value (USD Million) By Region

Figure 23: Global Immunohematology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Immunohematology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Immunohematology Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Immunohematology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Immunohematology Market Value (USD Million) By Region

Table 10: Global Immunohematology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Immunohematology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Immunohematology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Immunohematology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio-Rad Laboratories Basic Information And Sales Area

Table 31: Bio-Rad Laboratories. Products Portfolio

Table 32: Grifols Basic Information And Sales Area

Table 33: Grifols. Products Portfolio

Table 34: Immucor Basic Information And Sales Area

Table 35: Immucor. Products Portfolio

Table 36: Ortho Clinical Diagnostics Basic Information And Sales Area

Table 37: Ortho Clinical Diagnostics. Products Portfolio

Table 38: BD Basic Information And Sales Area

Table 39: BD. Products Portfolio

Table 40: Beckman Coulter Basic Information And Sales Area

Table 41: Beckman Coulter. Products Portfolio

Table 42: DIAGAST Basic Information And Sales Area

Table 43: DIAGAST. Products Portfolio

Table 44: Hemo bioscience Basic Information And Sales Area

Table 45: Hemo bioscience. Products Portfolio

Table 46: Institut de Biotechnologies Jacques Boy Basic Information And Sales Area

Table 47: Institut de Biotechnologies Jacques Boy. Products Portfolio

Table 48: MTC INVITRO Basic Information And Sales Area

Table 49: MTC INVITRO. Products Portfolio

Table 50: Seqirus Basic Information And Sales Area

Table 51: Seqirus. Products Portfolio

Table 52: Tulip Group Basic Information And Sales Area

Table 53: Tulip Group. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Immunohematology Market Value (USD Million) By Region

Table 59: Global Immunohematology Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Immunohematology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.67 billion
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad Laboratories; Grifols; Immucor; Ortho Clinical Diagnostics; BD; Beckman Coulter; DIAGAST; Hemo bioscience; Institut de Biotechnologies Jacques Boy; MTC INVITRO; Seqirus; Tulip Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Immunohematology Segmentation Breakdown7 items

Application

Blood-Related Diseases

HIV

Hepatitis

Types

Immunohematology Analyzers and Systems

Immunohematology Reagent

Regional Insights

Loading chart…

Key regional drivers5 items

North America: High adoption of automation in blood banking, robust reimbursement policies, and a mature ecosystem for diagnostic technologies.

Europe: Strong emphasis on blood safety regulations, aging population driving transfusion needs, and cross-border collaborations for innovation.

Asia Pacific: Rapid urbanization, increasing prevalence of blood disorders, and government-funded initiatives to expand healthcare infrastructure.

Latin America: Rising private-sector investments in diagnostics and growing partnerships with global immunohematology solution providers.

Middle East & Africa: Increasing focus on hospital modernization, rising disposable incomes, and expanding blood donation programs.

Competitive Landscape

Bio-Rad Laboratories: innovation pipeline in automated blood group testing

Grifols: vertical integration to secure plasma-derived product supply

Immucor: OEM tie-ups for hospital-specific diagnostic systems

Ortho Clinical Diagnostics: regional expansion in Asia-Pacific markets

BD: premium pricing for high-throughput immunoassay analyzers

Tulip Group: local manufacturing to reduce logistics costs in emerging markets

Key Immunohematology Companies12 items

Bio-Rad Laboratories

Grifols

Immucor

Ortho Clinical Diagnostics

Beckman Coulter

DIAGAST

Hemo bioscience

Institut de Biotechnologies Jacques Boy

MTC INVITRO

Seqirus

Tulip Group

Market Ecosystem

Raw material suppliers — deliver high-purity antibodies, antigens, and microtiter plate components for immunohematology reagent production

Technology providers — design next-generation analyzers and digital platforms for automated blood typing and cross-matching

OEMs/Manufacturers — assemble and validate immunohematology instrumentation and consumable test kits

System integrators — configure end-to-end solutions linking immunohematology systems with hospital LIS and lab automation

Distributors/Channel partners — manage regional logistics and compliance certifications for diagnostic product deployment

End users — include hospital transfusion services, blood banks, and research labs performing serological compatibility testing

Regulators/Standards bodies — enforce conformity to ISO, AABB, and FDA guidelines for diagnostic accuracy and patient safety

Recent Industry Insights

Analyst Overview

Table of Contents